IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC)
A specific genetic variant predicted better transplant outcomes and lower relapse rates in acute leukemia patients.
This retrospective multicenter cohort study examined IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC). IDH2 p.R172 was independently associated with no observed relapse and better progression-free and overall survival after transplantation.
What the study was
- Study design
- Retrospective multicenter cohort study
- Population
- Adults with IDH-mutated AML or MDS undergoing first allogeneic hematopoietic cell transplantation
- Sample size
- 101 patients
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Transplantation and cellular therapy
Why it surfaced
Retrospective multicenter cohort study; IDH2 p.R172 was independently associated with no observed relapse and better progression-free and overall survival after transplantation. Score kept conservative because only the PubMed abstract and metadata were reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.